Published online before print April 10, 2008

This Article Full Text (Rapid PDF) Supplemental Material All Versions of this Article: ajpath.2008.070207v1 172/5/1195    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cihakova, D. Articles by Rose, N. R. Search for Related Content PubMed PubMed Citation Articles by Cihakova, D. Articles by Rose, N. R.

Copyright © 2008 American Society for Investigative Pathology
American Journal of Pathology, doi:10.2353/ajpath.2008.070207

Accepted for publication February 5, 2008.

Article

Interleukin-13 Protects Against Experimental Autoimmune Myocarditis by Regulating Macrophage Differentiation

Daniela Cihakova^*@, Jobert G. Barin^*, Marina Afanasyeva, Miho Kimura^*, DeLisa Fairweather^*, Michael Berg^¶, Monica V. Talor^*, G. Christian Baldeviano^¶, Sylvia Frisancho, Kathleen Gabrielson^||, Djahida Bedja^||, and Noel R. Rose^*¶

From the Departments of Pathology,* and Molecular and Comparative Pathobiology,^|| and the Graduate Program in Immunology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; the W. Harry Feinstone Department of Molecular Microbiology and Immunology,^¶ and the Department of Environmental Health Sciences, the Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; and the Cardiovascular Research Group, Faculty of Medicine, University of Calgary, Calgary, Canada

^@ To whom correspondence should be addressed. E-mail: dcihako1{at}jhmi.edu.

	Abstract

We report here that interleukin (IL)-13 protects BALB/c mice from myocarditis, whether induced by peptide immunization or by viral infection. In contrast to mild disease in IL-4 knockout (KO) BALB/c mice, IL-13 KO BALB/c mice developed severe coxsackievirus B3 (CVB3)-induced autoimmune myocarditis and myocarditogenic peptide-induced experimental autoimmune myocarditis. Such severe disease was characterized by increased cardiac inflammation, increased total intracardiac CD45⁺ leukocytes, elevated anti-cardiac myosin autoantibodies, and increased cardiac fibrosis. Echocardiography revealed that IL-13 KO mice developed severe dilated cardiomyopathy with impaired cardiac function and heart failure. Hearts of IL-13 KO mice had increased levels of the proinflammatory and profibrotic cytokines IL-1, IL-18, interferon-, transforming growth factor-1, and IL-4 as well as histamine. The hallmark of the disease in IL-13 KO mice was the up-regulation of T-cell responses. CD4⁺ T cells were increased in IL-13 KO hearts both proportionally and in absolute number. Splenic T cells from IL-13 KO mice were highly activated, and myosin stimulation additionally increased T-cell proliferation. CD4⁺CD25⁺Foxp3⁺ regulatory T-cell numbers were decreased in the spleens of IL-13 KO mice. IL-13 deficiency led to decreased levels of alternatively activated CD206⁺ and CD204⁺ macrophages and increased levels of classically activated macrophages. IL-13 KO mice had increased caspase-1 activation, leading to increased production of both IL-1 and IL-18. Therefore, IL-13 protects against myocarditis by modulating monocyte/macrophage populations and by regulating their function.